Merck & Co / Eli Lilly / Eli Lilly and Company / Merck Research Laboratories / Lilly / CORPORATE GOVERNANCE 65 REGULATORY COMPLIANCE Pharmaceutical / Wellcome Trust / Corporate Responsibility Report Working Group / The GSK India / Novartis Group / GlaxoSmithKline / Pfizer Inc. / PMRs for US / Abbott India / Pfizer X Pharma / Novartis India / The Merck India / Pfizer India / Pharmacovigilance Framework Pharma / Eli Lilly X Pharma / Abbott Laboratories / CIPLA / /
Country
United States / India / /
Currency
USD / /
Event
Product Issues / FDA Phase / Product Recall / Business Partnership / /
Facility
Dundee University / High Court of Madras / /
IndustryTerm
treatment of multiple sclerosis / biopharmaceutical spin / pharmaceutical industry / drug product / private and public research networks / medicines and other products / pharmaceutical / healthcare / healthcare systems / web link / healthcare laws / pharmaceuticals / patient safety using product / pharmaceutical corporations / external audits / healthcare providers monitors / legal supply chain / /
Public Policy and Compliance Committee / Security and Exchange Commission / office of Corporate Responsibility / High Court of Madras / Public Policy and Responsibility Council / US Veterans Administration / Dundee University / European Medicines Agency / US Department of Justice / Compliance Committee / US Food and Drug Administration / Global Patient Safety Organization / office of Scientific and Technical Information Clearance / Lilly’s Global Patient Safety Organization / European Federation of Pharmaceutical Industries and Associations / Medical Affairs and Research Division / European Union / GSK’s Global Safety Board mission / Merck’s Global Compliance Organization / Ministry of Health / /
deputy coordinator / vice president / vice president of Global Patient Safety and Bioethics / physician / researcher / producer / Drug Controller General / executive vice president and president / /
Product
Janumet / Vioxx / Januvia / Product / Gilenya / /
PublishedMedium
the Pfizer India annual / The Novartis India annual / /
Drug Safety and Corporate Governance Kathy Moscou, Jillian Clare Kohler, and Joel Lexchin Pharmacovigilance in low and lower middle-income countries has not been commensurate with increasing access to medicines, despite